Kallistatin is a new inhibitor of angiogenesis and tumor growth

Blood

Volumn 100, Issue 9, 2002, Pages 3245-3252

  Miao, Robert Q ^a   Agata, Jun ^a   Chao, Lee ^a   Chao, Julie ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; CD31 ANTIGEN; COMPLEMENTARY DNA; HEMOGLOBIN; HEPARIN BINDING PROTEIN; KALLISTATIN; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CANCER INHIBITION; CAPILLARY DENSITY; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIMB ISCHEMIA; MALE; MOUSE; NONHUMAN; PERFUSION; PRIORITY JOURNAL; RAT; VASCULAR SMOOTH MUSCLE; VIRAL GENE DELIVERY SYSTEM;

EID: 0036839310     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0185     Document Type: Article

References (52)

1. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-674.
2. Auerbach W, Auerbach R. Angiogenesis inhibition: A review. Pharmac Ther. 1994;63:265-311.
3. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999;5:1359-1364.
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
5. Gastl G, Hermann T, Steurer M, et al. Angiogenesis as a target for tumor treatment. Oncology. 1997;54:177-184.
6. Folkman J. Angiogenesis. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Principles of Internal Medicine. 15th Ed. New York, NY: McGraw-Hill; 2001: 517-530.
7. Potempa J, Korzusand E, Travis J. The serpin superfamily of proteinase inhibitors: Structure, function, and regulation. J Biol Chem. 1994;269: 15957-15960.
8. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science. 1999;285:245-248.
9. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science. 1999;285:1926-1928.
10. Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nat Med. 2000;6:196-199.
11. Chao J, Tillman DM, Wang MY, Margolius HS, Chao L. Identification of a new tissue-kallikrein-binding protein. Biochem J. 1986;239:325-331.
12. Chao J, Chai KX, Chen LM, et al. Tissue kallikrein-binding protein is a serpin, I: Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem. 1990;265:16394-16401.
13. Chen LM, Ma JX, Liang YM, Chao L, Chao J. Tissue kallikrein-binding protein reduces blood pressure in transgenic mice. J Biol Chem. 1996;271: 27590-27594.
14. Chen LM, Chao L, Chao J. Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. Life Sciences. 1997;60: 1431-1436.
15. Chao J, Stallone JN, Liang YM, Chen LM, Chao L. Kallistatin is a potent new vasodilator. J Clin Invest. 1997 100:11-17.
16. Miao RQ, Murakami H, Song Q, Chao L, Chao J. Kallistatin stimulates vascular smooth muscle cell proliferation and migration in vitro and neointima formation in balloon-injured rat artery. Circ Res. 2000;86:418-424.
17. Chao J, Schmaler A, Chen LM, Yang Z, Chao L. Kallistatin, a novel human tissue kallikrein inhibitor: Levels in body fluids, blood cells, and tissues in health and disease. J Lab Clin Med. 1996;127: 612-620.
18. Ma JX, King LP, Yang Z, Crouch RK, Chao L, Chao J. Kallistatin in human ocular tissues: Reduced levels in vitreous fluids from patients with diabetic retinopathy. Curr Eye Res. 1996;15: 1117-1123.
19. Hatcher HC, Ma JX, Chao J, Chao L, Ottlecz A. Kallikrein-binding protein levels are reduced in the retinas of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci. 1997;38:658-664.
20. Wolf WC, Harley RA, Sluce D, Chao L, Chao J. Localization and expression of tissue kallikrein and kallistatin in human blood vessels. J Histochem Cytochem. 1999;47:221-228.
21. Zhou GX, Chao L, Chao J. Kallistatin: A novel human tissue kallikrein inhibitor: Purification, characterization, and reactive center sequence. J Biol Chem. 1992;267:25873-25880.
22. Chai KX, Chen LM, Chao J, Chao L. Kallistatin: A novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli. J Biol Chem. 1993;268:24498-24505.
23. He TC, Zhou S, daCosta LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 1998;95:2509-2514.
24. Becker TC, Noel RJ, Coats WS, et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol. 1994;43: 161-189.
25. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res. 1998;83:187-195.
26. Ziche M, Morbidelli L, Choudhuri R, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest. 1997;99:2625-2634.
27. Passaniti A, Taylor RM, Pili R, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenesis agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest. 1992;67:519-528.
28. Takeshita S, Isshiki T, Ochiai M, et al. Endothelium-dependent relaxation of collateral microvessels after intramuscular gene transfer of vascular endothelial growth factor in a rat model of hindlimb ischemia. Circulation. 1998;98:1261-1263.
29. Murohara T, Asahara T, Silver M, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998;101:2567-2578.
30. Lin KF, Chao J, Chao L. Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension. 1995;26:847-853.
31. Li H, Lu H, Griscelli F, et al. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Therapy. 1998;5:1105-1113.
32. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois, RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705-716.
33. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-396.
34. Silvestre JS, Mallat Z, Duriez M, et al. Antiangiogenic effect of interleukin-10 in ischemia-induced angiogenesis in mice hind-limb. Circ Res. 2000;87:448-452.
35. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
36. Couffinhal T, Silver M., Zheng LP, Kearney M, Witzenbichler B, Isner JM. Mouse model of angiogenesis. Am J Pathol. 1998;152:1667-1679.
37. Emanueli, C, Salis MB, Stacca T, et al. Targeting kinin B1 receptor for therapeutic neovascularization. Circulation. 2002;105:360-366.
38. Brem SS, Jensen HM, Gullino, PM. Angiogenesis as a marker of preneoplastic lesions of the human breast. Cancer. 1978;41:239-244.
39. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
40. Guidi AJ, Fisher L, Harirs JR, Schnitt SJ. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst. 1994;86-614-619.
41. Griscelli F, Li H, Bennaceur-Griscelli A, et al. Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci U S A. 1998;95:6367-6372.
42. Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SL. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci U S A. 2000;97:4802-4807.
43. Mahabeer R, Bhoola KD. Kallikrein and kinin receptor genes. Pharmacol Ther. 2000;88:77-89.
44. Tschesche H, Michaelis J, Kohnert U, Fedrowitz J, Oberhoff R. Tissue kallikrein effectively activates latent matrix degrading metalloenzymes. Adv Exp Med Biol. 1989;247A:545-548.
45. Desrivieres S, Lu H, Peyri N, Soria C, Legrand Y, Menashi S. Activation of the 92kDa type IV collagenase by tissue kallikrein. J Cell Physiol. 1993;157:587-593.
46. Wolf WC, Evans DM, Chao L, Chao J. A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. Am J Pathol. 2001;159:1797-1805.
47. Janciauskiene S. Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles. Biochim Biophys Acta. 2001;1535:221-235.
48. Gitay-Goren H, Soker S, Vlodavsky I, Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem. 1992;267:6093-6098.
49. Iozzo RV, San Antonio JD. Heparan sulfate proteoglycans: Heavy hitters in the angiogenesis arena. J Clin Invest. 2001;108:349-355.
50. Chen VC, Chao L, Pimenta DC, Bledsoe G, Juliano L, Chao J. Identification of a major heparin-binding site in kallistatin. J Biol Chem. 2001;276:1276-84.
51. Sasaki T, Larsson H, Kreuger J, et al. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis/inhibitor endostatin. EMBO J. 1999;18:6240-6248.
52. Dixelius J, Larsson H, Sasaki T, et al. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood. 2000;95:3403-3411.